Bisphosphonates and skeletal morbidity in patients with metastatic cancer

Bhandari, Mohit
November 2003
CMAJ: Canadian Medical Association Journal;11/11/2003, Vol. 169 Issue 10, p1053
Academic Journal
Summarizes the study "Systematic Review of Role of Bisphosphonates on Skeletal Morbidity in Metastatic Cancer," by J. R. Ross, Y. Saunders, P.M. Edmonds, S. Patel, K.E. Broadley and S. R. Johnston, published in the 2003 issue of the "British Medical Journal." Information on metastatic bone disease; Experimental details; Results.


Related Articles

  • Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. Ross, J R; Saunders, Y; Broadley, K E; Edmonds, P M; Patel, S; Johnston, S R D // BMJ: British Medical Journal (International Edition);8/30/2003, Vol. 327 Issue 7413, p469 

    Objective: To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases. Data sources: Electronic databases, scanning reference lists, and consultation with experts and pharmaceutical companies. Foreign language papers were included....

  • Bisphosphonates:Expanded Roles in the Treatment of Patients With Cancer. Viale, Pamela Hallquist; Yamamoto, Deanna Sanchez // Clinical Journal of Oncology Nursing;Jul/Aug2003, Vol. 7 Issue 4, p393 

    Bisphosphonates are important inhibitors of osteoclastic bone resorption seen in patients with bone metastases associated with malignancy.Bisphosphonates are used in the treatment of patients with bone metastases and have been shown to reduce skeletal-related events and symptoms,contributing...

  • How Do Bisphosphonates Inhibit Bone Metastasis In Vivo? Fournier, Pierrick G.; Stresing, Verena; Ebetino, Frank H.; Cl�zardin, Philippe // Neoplasia;Jul2010, Vol. 12 Issue 7, p571 

    Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and have demonstrated clinical utility in the treatment of patients with osteolytic bone metastases. They also exhibit direct antitumor activity in vitro and can reduce skeletal tumor burden and inhibit the formation of...

  • Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Quinn, J. E.; Brown, L. G.; Zhang, J.; Keller, E. T.; Vessella, R. L.; Corey, E. // Prostate Cancer & Prostatic Diseases;2005, Vol. 8 Issue 3, p253 

    Zoledronic acid (ZA) has been shown to inhibit prostate tumor growth in vitro and have beneficial effects in patients with advanced prostate cancer (CaP). The aim of this study was to determine whether ZA exhibits direct anti-tumor effects on CaP cells in vivo. To distinguish the effects of...

  • Advances in Supportive Care of Patients With Cancer and Bone Metastases:Nursing Implications of Zoledronic Acid. Maxwell, Cathy; Swift, Regina; Goode, Melissa; Doane, Lois; Rogers, Miriam // Clinical Journal of Oncology Nursing;Jul/Aug2003, Vol. 7 Issue 4, p403 

    The knowledge and training of nursing staff is essential for the safety and comfort of patients receiving IV therapies. The use of IV bisphosphonates as an adjunct to standard antineoplastic therapies in patients with advanced cancer is becoming widespread.Zoledronic acid and pamidronate ...

  • Production, Quality Control and Biological Evaluation of 153Sm-EDTMP in Wild-Type Rodents. Bahrami-Samani, Ali; Ghannadi-Maragheh, Mohammad; Jalilian, Amir Reza; Meftahi, Moein; Shirvani-Arani, Simindokht; Moradkhani, Sedigheh // Iranian Journal of Nuclear Medicine;2009, Vol. 17 Issue 2, p12 

    Introduction: Nowadays various bone pain palliative therapeutic agents have been developed for bone metastases. Among those, 153Sm-ethylenediamine tetramethylene phosphonic acid (153Sm-EDTMP) is the major therapeutic agent which is widely used in the world. In this study, production, quality...

  • Spontaneous bisphosphonate-related osteonecrosis of the left hemi-mandible: Similarities with phossy jaw. Campisi, Giuseppina; Domenico, Compilato; Angelo, Itro; Lo Muzio, Lorenzo; Colella, Giuseppe // Indian Journal of Dental Research;Sep/Oct2012, Vol. 23 Issue 5, p683 

    Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term side effects BP, a form of avascular osteonecrosis of the jaw has been reported. Although, invasive oral local procedures are often present in clinical history of patients suffering from...

  • Effects of proteasome inhibitors on bone cancer. Terpos, Evangelos; Christoulas, Dimitrios // IBMS BoneKEy;Apr2014, Vol. 11 Issue 4, p-1 

    Bone metastasis is a frequent complication of cancer, occurring in up to 70% of patients with advanced breast or prostate cancer while bone disease is also the characteristic clinical feature of multiple myeloma. Skeletal-related events can be devastating, with major effect on quality of life...

  • Zoledronic Acid: Its Use in the Treatment of Breast Cancer. Luís, Inês Vaz; Casimiro, Sandra; Ribeiro, Joana; Luís Costa // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p913 

    Breast cancer is a very common diagnosis in women; approximately 30% of patients with breast cancer will develop bone metastases. In addition, breast cancer patients experience adjuvant treatment related bone loss. Bisphosphonates (BPs) are the standard of care for maintaining bone health in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics